**Core Concept**
Doxorubicin, an anthracycline antibiotic, is a widely used chemotherapeutic agent for various cancers. Its cardiotoxicity is a major side effect, leading to heart failure and other cardiac complications. The mechanisms underlying doxorubicin-induced cardiotoxicity involve the generation of reactive oxygen species (ROS), mitochondrial dysfunction, and disruption of the cardiac sarcoplasmic reticulum.

**Why the Correct Answer is Right**
The cardiotoxicity of doxorubicin can be mitigated by using Dexrazoxane, a cardioprotective agent that acts as a metal chelator. Dexrazoxane binds to iron and other metals, thereby reducing the formation of ROS and protecting the cardiac sarcoplasmic reticulum from doxorubicin-induced damage. This leads to a decrease in the incidence of cardiotoxicity and cardiac complications associated with doxorubicin treatment.

**Why Each Wrong Option is Incorrect**
**Option A:** Beta-blockers are used to manage heart failure symptoms but do not directly reduce doxorubicin-induced cardiotoxicity.
**Option B:** ACE inhibitors are used to treat hypertension and heart failure but do not have a direct role in preventing doxorubicin-induced cardiotoxicity.
**Option C:** Amiodarone is an antiarrhythmic medication used to treat various cardiac arrhythmias but is not effective in preventing doxorubicin-induced cardiotoxicity.

**Clinical Pearl / High-Yield Fact**
Dexrazoxane is a cardioprotective agent that can be used to reduce the risk of cardiotoxicity associated with anthracycline antibiotics like doxorubicin. It is essential to consider using dexrazoxane in patients receiving high-dose doxorubicin chemotherapy to minimize cardiac complications.

**Correct Answer:** D. Dexrazoxane